November, 2020

No. 105 (11)

2019 Impact Factor: 7.116
Centenary Review

Pediatric acute lymphoblastic leukemia

Overall survival of children with ALL now exceeds 90% but, with the conventional approach, chemotherapy intensity has reached the limit of tolerance. New approaches based on better knowledge of the pathophysiological mechanisms of the disease in each patient will further improve patients' prognosis.

Hiroto Inaba et al.


Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

This preclinical study investigated the anti-tumor effect of the first-in-class antibody drug conjugate MEN1309/OBT076 targeting CD205. Its in vitro activity appeared highly correlated with target expression, and in vivo studies demonstrated strong anti-tumor activity in lymphoma.

Eugenio Gaudio et al.


Migfilin supports hemostasis and thrombosis through regulating platelet αIIbβ3 outside-in signaling.

Through participation in cytoskeleton reorganization of platelets, migfilin is involved in cellular functions such as adhesion, morphological change, and motility. Migfilin knock-out mice revealed that this molecule is a pivotal positive regulator of hemostasis and thrombosis. Modulation of outside-in signaling of platelet aIIbβ3 plays a key role in this function.

Yangfan Zhou et al.

Letters to the Editor

Long-term outcomes after splenectomy in children with immune thrombocytopenia: an update on the registry data from the Intercontinental Cooperative ITP Study Group

Two hundred thirty-nine patients with a median follow-up of 25 months were included in the analysis. 93% of patients achieved complete or partial remission, with minimal adverse events in the peri-operative period. Older age was an independent predictor of response.

Maria L. Avila et al.